Results 81 to 90 of about 39,316 (219)
Unraveling the Role of Allo-Antibodies and Transplant Injury. [PDF]
, 2016 Alloimmunity driving rejection in the context of solid organ transplantation can be grossly divided into mechanisms predominantly driven by either T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR), though the co-existence of both ...
Matsuda, Yoshiko, Sarwal, Minnie M
core +2 more sources
Interdisciplinary Medicine, EarlyView.SUMOylation, a dynamic post‐translational modification, acts as a master regulator at the heart of tumor malignancy. Our work delineates how the SUMOylation cycle—mediated by E1/E2/E3 enzymes and reversed by SENPs—orchestrates multiple hallmarks of cancer. The central pathway converges on three critical pathological axes: 1.
Yimao Wu +6 more
wiley +1 more source
BMC Cancer, 2012 Background Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory.
Wang Cun +12 more
doaj +1 more source
Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone
JEADV Clinical Practice, EarlyView.ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri +2 more
wiley +1 more source
PLoS ONE, 2016 This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and ...
Amanda M DiNofia +7 more
doaj +1 more source
Cancer stem cells in prostate cancer: implications for targeted therapy [PDF]
, 2017 Prostate cancer (PCa) is the most frequently diagnosed cancer in men and the second most common cause of cancer-related mortality among men in the developed world.
Castelo-Branco, Pedro +5 more
core +1 more source
Haematologica, 2015 Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.
Marianne Kraus +15 more
doaj +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu +5 more
wiley +1 more source
Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
Journal of Global Oncology, 2017 Purpose: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM).
Kaladada I. Korubo +3 more
doaj +1 more source
Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts [PDF]
, 2019 Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission.
Atkinson, Emily G. +7 more
core +1 more source